Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
27. November 2024 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare...
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
06. November 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract...
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
30. Oktober 2024 16:20 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after...
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
08. August 2024 16:05 ET
|
Coherus BioSciences, Inc.
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as...
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
01. August 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after...
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
27. Juni 2024 08:26 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
05. Juni 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice...
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
30. Mai 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare...
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23. Mai 2024 17:51 ET
|
Coherus BioSciences, Inc.
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T...
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
23. Mai 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual...